New Celgene meds power forward, but Revlimid's still the Big Kahuna

Celgene ($CELG) edged past analyst estimates for the fourth quarter and full year, with earnings of $3.71 per share and $7.67 billion in revenue for 2014. Its powerhouse remedy for multiple myeloma, Revlimid, still accounts for the lion's share of those sales, at $4.98 billion in 2014 revenue, an increase of 16%. Its new myeloma treatment Pomalyst is coming up strong, however, with $202 million for Q4 and $680 million for 2014, its first full year on the market. Release